SCHEMBL1241612

SCHEMBL1241612

CN(c1ccc(Br)cc1F)C1CCCC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.39
RXFP1 Q9HBX9 1/20 0.39
NPSR1 Q6W5P4 3/20 0.39
KMT2A Q03164 2/20 0.39
DDB1 Q16531 1/20 0.38
CRBN Q96SW2 1/20 0.38
ALDH1A1 P00352 3/20 0.37
KDM1A O60341 2/20 0.37
KDM1B Q8NB78 1/20 0.37
LMNA P02545 1/20 0.36
GAA P10253 1/20 0.36
JAK2 O60674 1/20 0.35
JAK1 P23458 1/20 0.35
JAK3 P52333 1/20 0.35
PDE3B Q13370 1/20 0.35
PDE3A Q14432 1/20 0.35
PYCR1 P32322 1/20 0.35
MEN1 O00255 1/20 0.34
POLB P06746 1/20 0.34
HTT P42858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1242072 0.83 DDB1 (0.52) MAPTNPSR1DDB1CRBNALDH1A1
SCHEMBL16538261 0.82 ALDH1A1 (0.42) MAPTRXFP1NPSR1KMT2AALDH1A1
Methylamine SCHEMBL27922119 0.79 CYP2D6 (0.44) MAPTRXFP1NPSR1KMT2AALDH1A1
Methylamine SCHEMBL27615328 0.78 LMNA (0.46) MAPTRXFP1NPSR1KMT2AALDH1A1
Methylamine SCHEMBL27987009 0.76 LMNA (0.47) MAPTNPSR1KMT2AALDH1A1LMNA
SCHEMBL29157521 0.75 DDB1 (0.55) DDB1CRBNALDH1A1HTTIDO1
SCHEMBL29003938 0.75 ALDH1A1 (0.40) MAPTRXFP1NPSR1KMT2AALDH1A1
SCHEMBL16538184 0.74 HTT (0.54) MAPTNPSR1KMT2AALDH1A1LMNA
SCHEMBL1887433 0.74 PYCR1 (0.42) KMT2AALDH1A1KDM1AKDM1BLMNA
SCHEMBL1240861 0.74 EPHX2 (0.39) MAPTNPSR1ALDH1A1LMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8586614-B2 Urea glucokinase activators NOVO NORDISK A/S (DK) 2013-11-19 US disclosed
CN-101263131-B Urea glucokinase activators TRANSTECH PHARMA INC 2013-04-24 CN disclosed
EP-2377856-A1 Urea glucokinase activators NOVO NORDISK A/S (DK) 2011-10-19 EP disclosed
US-20110077234-A1 Urea Glucokinase Activators NOVO NORDISK A/S (DK) 2011-03-31 US disclosed
US-7884210-B2 {2-[3-(2-Cyclohex-1-enyl-ethyl)-3-(trans-4-methyl-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid; for treatment of type 2 diabetes NOVO NORDISK A/S (DK) 2011-02-08 US disclosed
US-20090105482-A1 Urea Glucokinase Activators NOVO NORDISK A/S (DK) 2009-04-23 US disclosed
CN-101263131-A Urea glucokinase activators NOVO NORDISK AS (US) 2008-09-10 CN disclosed
EP-1904467-A1 UREA GLUCOKINASE ACTIVATORS Novo Nordisk A/S (DK) 2008-04-02 EP disclosed
WO-2007006814-A1 UREA GLUCOKINASE ACTIVATORS NOVO NORDISK A/S (DK) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105482-A1 Urea Glucokinase Activators GCK, GCKR, HK2 MAPT 2360/4885RXFP1 3072/4885NPSR1 4621/4885
US-20110077234-A1 Urea Glucokinase Activators GCK, GCKR, HK2 MAPT 2360/4885RXFP1 3072/4885NPSR1 4621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.